Skip to main content
. Author manuscript; available in PMC: 2021 Sep 1.
Published in final edited form as: Cell Metab. 2020 Jul 28;32(3):353–365.e8. doi: 10.1016/j.cmet.2020.07.002

Figure 4. SRI-37330 controls alpha cell glucagon secretion.

Figure 4

(a) Proglucagon mRNA expression (NS, not significant) from αTC1-6 alpha cells incubated with or without SRI-37330, mean ± s.e.m. of 3 independent experiments.

(b) Glucagon content (N.S.) in αTC1-6 alpha cells incubated with or without SRI-37330, n = 3 independent experiments.

(c) Glucagon secretion from αTC1-6 alpha cells incubated with or without SRI-37330 (t4 =3.84, *P = 0.0185), n = 3 independent experiments.

(d) Glucagon secretion from αTC1-6 alpha cells with or without TXNIP knockdown (KD) (t4 = 3.50, *P = 0.0248), n = 3 independent experiments.

(e) Glucagon secretion from αTC1-6 alpha cells with or without TXNIP overexpression (OE) (t4 = 3.35, *P = 0.0285), n = 3 independent experiments.

(f) Effects of SRI-37330 on glucagon secretion stimulated by arginine (20 mM) and norepinephrine (10μM) (N.S.).

(g) Effects of SRI-37330 on glucagon secretion stimulated by low glucose (1.67 mM) (N.S.).

(h) Comparison of hypoglycemia as assessed by blood glucose 15min after a bolus of insulin (1U/kg) in fasting SRI-37330 treated and untreated mice (N.S.). n=4 mice per group.